355,336 Shares in Adaptive Biotechnologies Corporation $ADPT Bought by Legal & General Group Plc

Legal & General Group Plc purchased a new stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 355,336 shares of the company’s stock, valued at approximately $7,622,000.

Other large investors have also bought and sold shares of the company. California State Teachers Retirement System boosted its holdings in Adaptive Biotechnologies by 1.0% during the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after acquiring an additional 933 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Adaptive Biotechnologies by 6.8% in the first quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock valued at $205,000 after purchasing an additional 941 shares during the last quarter. Captrust Financial Advisors raised its holdings in shares of Adaptive Biotechnologies by 7.6% in the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after purchasing an additional 1,119 shares during the last quarter. Assetmark Inc. raised its holdings in shares of Adaptive Biotechnologies by 46.4% in the first quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock valued at $61,000 after purchasing an additional 1,401 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors.

Adaptive Biotechnologies Stock Performance

NASDAQ ADPT opened at $24.66 on Thursday. Adaptive Biotechnologies Corporation has a 52-week low of $12.00 and a 52-week high of $26.87. The company has a 50-day simple moving average of $23.32 and a 200 day simple moving average of $17.85. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. The company has a market capitalization of $3.94 billion, a PE ratio of -60.15 and a beta of 2.09.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The company had revenue of $71.55 million during the quarter, compared to the consensus estimate of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The business’s revenue was up 21.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.17) EPS. On average, research analysts predict that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on ADPT. Piper Sandler upped their price objective on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Guggenheim boosted their target price on Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Morgan Stanley upped their target price on Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. decreased their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Finally, BTIG Research lifted their price target on Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $24.42.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, Director Peter M. Neupert sold 124,690 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $25.15, for a total transaction of $3,135,953.50. Following the completion of the transaction, the director directly owned 130,625 shares of the company’s stock, valued at approximately $3,285,218.75. This represents a 48.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Harlan S. Robins sold 492,400 shares of the stock in a transaction on Tuesday, July 21st. The shares were sold at an average price of $21.89, for a total value of $10,778,636.00. Following the transaction, the insider directly owned 812,058 shares of the company’s stock, valued at approximately $17,775,949.62. This trade represents a 37.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 2,011,584 shares of company stock worth $45,765,999 over the last 90 days. Corporate insiders own 5.70% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.